Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Hauben

Showing results (41-50 of 112) with videos related to

Pageof 12
Sort By:
Pharmacoepidemiology and Drug Safety|June 3, 2017
Does serious consequential masking exist? An updateManfred Hauben, François Maignen
Drug Safety|July 1, 2026
The Bidirectionality of Lawyer Reporting Bias in Disproportionality AnalysisManfred Hauben, Rave Harpaz
Drug Safety|August 19, 2007
Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade oreManfred Hauben, Jeffrey K Aronson
Drug Safety|February 25, 2009
Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitionsManfred Hauben, Jeffrey K Aronson
BMJ (Clinical Research Ed.)|December 16, 2006
Anecdotes that provide definitive evidenceJeffrey K Aronson, Manfred Hauben
Journal of Clinical Pharmacology|May 17, 2013
A quantitative analysis of the spontaneous reporting of congestive heart failure-related adverse events with systemic anti-fungal drugsManfred Hauben, Eric Y Hung
Drug Safety|June 18, 2010
A decade of data mining and still countingManfred Hauben, G Niklas Norén
Pharmacoepidemiology and Drug Safety|October 5, 2006
Data mining for signals in spontaneous reporting databases: proceed with cautionWendy P Stephenson, Manfred Hauben
Pharmacoepidemiology and Drug Safety|September 1, 2005
Signal detection in pharmacovigilance: empirical evaluation of data mining toolsK Arnold Chan, Manfred Hauben
Drug Safety|October 17, 2002
The association of erythromycin and infantile hypertrophic pyloric stenosis: causal or coincidental?Manfred Hauben, Guy W Amsden
Pageof 12

Showing results (41-50 of 112) with videos related to

Sort By:
Pageof 12
Pharmacoepidemiology and Drug Safety|June 3, 2017
Does serious consequential masking exist? An updateManfred Hauben, François Maignen
Drug Safety|July 1, 2026
The Bidirectionality of Lawyer Reporting Bias in Disproportionality AnalysisManfred Hauben, Rave Harpaz
Drug Safety|August 19, 2007
Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade oreManfred Hauben, Jeffrey K Aronson
Drug Safety|February 25, 2009
Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitionsManfred Hauben, Jeffrey K Aronson
BMJ (Clinical Research Ed.)|December 16, 2006
Anecdotes that provide definitive evidenceJeffrey K Aronson, Manfred Hauben
Journal of Clinical Pharmacology|May 17, 2013
A quantitative analysis of the spontaneous reporting of congestive heart failure-related adverse events with systemic anti-fungal drugsManfred Hauben, Eric Y Hung
Drug Safety|June 18, 2010
A decade of data mining and still countingManfred Hauben, G Niklas Norén
Pharmacoepidemiology and Drug Safety|October 5, 2006
Data mining for signals in spontaneous reporting databases: proceed with cautionWendy P Stephenson, Manfred Hauben
Pharmacoepidemiology and Drug Safety|September 1, 2005
Signal detection in pharmacovigilance: empirical evaluation of data mining toolsK Arnold Chan, Manfred Hauben
Drug Safety|October 17, 2002
The association of erythromycin and infantile hypertrophic pyloric stenosis: causal or coincidental?Manfred Hauben, Guy W Amsden
Pageof 12